BCL2 and myelodysplastic syndrome: Azacytidine may synergistically inhibit the pro-survival MCL1- and BCL-XL based pathways, thereby increasing the dependence of myeloid malignancies (AML, MDS and MPNs) cells on BCL-2 (15, 16).